Nosso blog

Junho 8, 2017

Why Stomach Balloons are the Future of Healthcare

The rise of the balloon field is not only revolutionizing obesity but also emblematic of shifts occurring in healthcare systems all around the world. Dr. Shantanu Gaur explores these themes in his latest post on MedCityNews. Click here for the full post.

Abril 3, 2017

Allurion Repays Massachusetts Life Sciences Center

5 years ago, the Massachusetts Life Sciences Center​ awarded us an Accelerator Loan that made the R&D and clinical testing possible for us to secure private investment. The loan program has helped countless companies grow and expand in Massachusetts. Today, we announce repayment of that loan! Thank you to the Center, Senator Karen Spilka​, and Governor Charlie Baker​ for your support. We will continue to make Massachusetts proud!

Março 5, 2017

Obesity is Complex. Why Aren’t its Treatments?

In a recent article on MedCityNews, Dr. Shantanu Gaur and Michael Fergusson (CEO of Ayogo) explore the next generation of more personalized obesity treatments. Click here for the article.

Maio 6, 2016

Allurion Technologies’ Elipse Intragastric Balloon Receives Prestigious SAGES Innovation Award

Allurion Technologies announced today that its flagship product, the Elipse Balloon, has received the prestigious Emerging Technology Innovation Award from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). The Elipse Device is the world’s first procedureless™ intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is the first intragastric balloon to receive this award. The Elipse System received European Union CE marking in late 2015 and is now available at leading weight loss centers in the United Kingdom, Italy and France. Plans for commercial expansion within Europe and in the Middle East are underway. For the…

Fevereiro 28, 2015

Slow and Steady Doesn’t Win the Race: It’s a Tie

A recently published paper in Lancet Diabetes and Endocrinology challenges the widely held notion that gradual weight loss is associated with better long-term outcomes than rapid weight loss. Purcell and colleagues randomized 200 people to either a rapid (12 weeks) or gradual (36 weeks) weight loss program (Phase 1) and then followed those who lost at least 12.5% of their weight for over 3 years to assess long-term outcomes (Phase 2). They concluded the following: After nearly 3 years of follow-up, people in both groups maintained ~30% of the weight they had lost (see figure) 81% of people in the rapid…